InfuPharma Targets Insurer For Avastin Defense

Law360, New York (April 23, 2012, 7:54 PM EDT) -- InfuPharma LLC on Thursday dragged a Chartis Inc. affiliate into a dispute with another insurer over defense of the pharmaceutical distributor in suits alleging InfuPharma improperly compounded Genentech Inc.'s cancer drug Avastin, leading to eye injury and blindness.

In a third-party complaint filed in the Southern District of Florida, InfuPharma said Chartis affiliate Commerce and Industry Insurance Co. has a duty to defend it in the underlying suits under a policy that provides $2 million in coverage for "products completed operations" and another $2 million of...
To view the full article, register now.